A share price of Mirum Pharmaceuticals Inc [MIRM] is currently trading at $77.39, up 1.75%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MIRM shares have gain 4.77% over the last week, with a monthly amount glided 29.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On April 17, 2024, Stifel initiated with a Buy rating and assigned a price target of $48 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $58 on December 18, 2023. Morgan Stanley started tracking with a Overweight rating for this stock on November 13, 2023, and assigned it a price target of $60. In a note dated October 24, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $50 on this stock.
Mirum Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $36.86 and $76.45. Currently, Wall Street analysts expect the stock to reach $85 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $77.39 at the most recent close of the market. An investor can expect a potential return of 9.83% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Trailing Twelve Months sales for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] were 429.16M which represents 64.09% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.25 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 75.88 points at the first support level, and at 74.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 78.50, and for the 2nd resistance point, it is at 79.60.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] is 3.13. Also, the Quick Ratio is 2.97, while the Cash Ratio stands at 1.58. Considering the valuation of this stock, the price to sales ratio is 9.06, the price to book ratio is 15.18.
Transactions by insiders
Recent insider trading involved SAIRA RAMASASTRY, Director, that happened on Sep 08 ’25 when 17000.0 shares were purchased. CHIEF EXECUTIVE OFFICER, Peetz Christopher completed a deal on Aug 11 ’25 to sell 40000.0 shares. Meanwhile, Officer CHRISTOPHER PEETZ bought 40000.0 shares on Aug 11 ’25.
